keyword
MENU ▼
Read by QxMD icon Read
search

Thompson melanoma

keyword
https://www.readbyqxmd.com/read/29789324/smoking-and-cutaneous-melanoma-findings-from-the-qskin-sun-and-health-cohort-study
#1
Jean Claude Dusingize, Catherine M Olsen, Nirmala Pandeya, Bridie S Thompson, Penelope M Webb, Adèle C Green, Rachel E Neale, David C Whiteman
BACKGROUND: Previous studies suggest that smokers have lower risks of cutaneous melanoma than non-smokers, but data from population-based prospective studies are scarce. We investigated associations between smoking and melanoma in a cohort study purpose-designed to investigate skin cancer outcomes. METHODS: Participants with no prior history of melanoma (n=38,697) completed a risk factor survey at baseline (2011). Patients were followed through linkage to the cancer registry...
May 22, 2018: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/29776637/an-update-regarding-the-molecular-genetics-of-melanocytic-neoplasms-and-the-current-applications-of-molecular-genetic-technologies-in-their-diagnosis-and-treatment
#2
REVIEW
Katrin Kiavash, Martin H Bluth, Andrew David Thompson
Molecular genetic technologies are used to aid in diagnosis and treatment of borderline melanocytic tumors as an adjuvant to the gold standard histopathologic evaluation. A specific set of fluorescence in situ hybridization probes is widely used to aid in diagnosing challenging melanocytic lesions. New melanoma probe cocktails have revealed increased sensitivity and specificity in ambiguous melanocytic cases. Array comparative genomic hybridization is a more complex technology used for the work-up of diagnostically problematic Spitzoid melanocytic proliferations...
June 2018: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/29775310/fragment-based-discovery-of-a-potent-orally-bioavailable-inhibitor-which-modulates-the-phosphorylation-and-catalytic-activity-of-erk1-2
#3
Tom D Heightman, Valerio Berdini, Hannah Braithwaite, Ildiko Maria Buck, Megan Cassidy, Juan Castro, Aurelie Courtin, James E H Day, Charlotte East, Lynsey Fazal, Brent Graham, Charlotte M Griffiths-Jones, John F Lyons, Vanessa Martins, Sandra Muench, Joanne M Munck, David Norton, Marc O'Reilly, Nick Palmer, Puja Pathuri, Michael Reader, David C Rees, Sharna J Rich, Caroline Richardson, Harpreet Saini, Neil T Thompson, Nicola G Wallis, Hugh Walton, Nicola E Wilsher, Alison J-A Woolford, Michael Cooke, David Cousin, Stuart Onions, Jonathan Shannon, John Watts, Christopher W Murray
Aberrant activation of the MAPK pathway drives cell proliferation in multiple cancers. Inhibitors of BRAF and MEK kinases are approved for the treatment of BRAF mutant melanoma, but resistance frequently emerges, often mediated by increased signalling through ERK1/2. Here we describe the fragment based generation of ERK1/2 inhibitors which block catalytic phosphorylation of downstream substrates such as RSK but also modulate phosphorylation of ERK1/2 by MEK without directly inhibiting MEK. X-ray crystallographic and biophysical fragment screening followed by structure-guided optimization and growth from the hinge into a pocket proximal to the C-α helix afforded highly potent ERK1/2 inhibitors with excellent kinome selectivity...
May 18, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29764330/factors-influencing-the-provision-of-fertility-counseling-and-impact-on-quality-of-life-in-adolescents-and-young-adults-with-cancer
#4
Gemma Skaczkowski, Victoria White, Kate Thompson, Helen Bibby, Michael Coory, Lisa M Orme, Rachel Conyers, Marianne B Phillips, Michael Osborn, Rosemary Harrup, Antoinette Anazodo
PURPOSE: This study investigated the impact of fertility-related discussions on Adolescent and Young Adult (AYA) cancer patients' quality of life (QoL) and the factors influencing provision of these discussions. METHODS: Recruitment was conducted through population-based state cancer registries. Eligible AYAs were 15-24 years at diagnosis, 3-24 months postdiagnosis, with any cancer (except early stage melanoma). As part of a larger survey, AYAs were asked about their experiences of fertility-related discussions and QoL (FACT-G)...
May 15, 2018: Journal of Psychosocial Oncology
https://www.readbyqxmd.com/read/29757889/utilizing-t-cell-activation-signals-1-2-and-3-for-tumor-infiltrating-lymphocytes-til-expansion-the-advantage-over-the-sole-use-of-interleukin-2-in-cutaneous-and-uveal-melanoma
#5
René J Tavera, Marie-Andrée Forget, Young Uk Kim, Donastas Sakellariou-Thompson, Caitlin A Creasy, Ankit Bhatta, Orenthial J Fulbright, Renjith Ramachandran, Shawne T Thorsen, Esteban Flores, Arely Wahl, Audrey M Gonzalez, Christopher Toth, Seth Wardell, Rahmatu Mansaray, Laszlo G Radvanyi, Dan S Gombos, Sapna P Patel, Patrick Hwu, Rodabe N Amaria, Chantale Bernatchez, Cara Haymaker
In this study, we address one of the major critiques for tumor-infiltrating lymphocyte (TIL) therapy-the time needed for proper expansion of a suitable product. We postulated that T-cell receptor activation in the first phase of expansion combined with an agonistic stimulation of CD137/4-1BB and interleukin-2 would favor preferential expansion of CD8 TIL. Indeed, this novel 3-signal approach for optimal T-cell activation resulted in faster and more consistent expansion of CD8CD3 TIL. This new method allowed for successful expansion of TIL from cutaneous and uveal melanoma tumors in 100% of the cultures in <3 weeks...
May 11, 2018: Journal of Immunotherapy
https://www.readbyqxmd.com/read/29742195/longitudinal-melanonychia-biopsy-what-not-to-do
#6
Jorge Ocampo-Garza, Joana Mendes Bretas, Daiane Matana, Paula Jacomini Sobral, Curtis T Thompson, Martin Zaiac, Antonella Tosti
The nail matrix biopsy is an important technique in confirming or excluding a diagnosis of melanoma in a patient with longitudinal melanonychia. Dermatologists are the first-line diagnosticians for these pigmented lesions of the nail unit, however, for different reasons, some are reluctant to perform a nail biopsy. This case demonstrates how a poor biopsy technique resulted in a misdiagnosis in a patient with melanoma in situ. J Drugs Dermatol. 2018;17(5):587-588.
May 1, 2018: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29733814/physician-skin-checks-before-the-diagnosis-of-melanoma-correlate-with-tumor-characteristics
#7
Catherine M Olsen, Nirmala Pandeya, Bridie S Thompson, Jean Claude Dusingize, Adele C Green, Rachel E Neale, David C Whiteman
No abstract text is available yet for this article.
May 4, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29695633/astx660-a-novel-non-peptidomimetic-antagonist-of-ciap1-2-and-xiap-potently-induces-tnf-%C3%AE-dependent-apoptosis-in-cancer-cell-lines-and-inhibits-tumor-growth
#8
George A Ward, Edward J Lewis, Jong Sook Ahn, Christopher N Johnson, John F Lyons, Vanessa Martins, Joanne M Munck, Sharna J Rich, Tomoko Smyth, Neil T Thompson, Pamela A Williams, Nicola E Wilsher, Nicola G Wallis, Gianni Chessari
Due to their roles in the evasion of apoptosis, Inhibitor of Apoptosis Proteins (IAPs) are considered attractive targets for anti-cancer therapy. Antagonists of these proteins have the potential to switch pro-survival signaling pathways in cancer cells towards cell death. Various SMAC-peptidomimetics with inherent cIAP selectivity have been tested clinically and demonstrated minimal single agent efficacy. ASTX660 is a potent, non-peptidomimetic, antagonist of cIAP1/2 and XIAP, discovered using fragment-based drug design...
April 25, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29691736/metastatic-melanoma-to-the-colon-rectum-and-anus-a-50-year-experience
#9
Jin-Soo Park, Kheng-Seong Ng, Robyn P M Saw, John F Thompson, Christopher J Young
BACKGROUND: Melanoma metastatic to the large bowel (colon, rectum, and anus) is rarely diagnosed, with more than 95% of large bowel metastases identified post-mortem. The incidence, natural history, and survival rates of patients with large bowel melanoma metastases are poorly documented in the literature. OBJECTIVE: This study aimed to identify the incidence, clinical characteristics, and survival of patients with large bowel melanoma metastases. METHODS: A review was undertaken of all patients with melanoma treated over a 50-year period (1964-2014) at a tertiary referral center...
April 24, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29599411/cd103-tumor-resident-cd8-t-cells-are-associated-with-improved-survival-in-immunotherapy-na%C3%A3-ve-melanoma-patients-and-expand-significantly-during-anti-pd-1-treatment
#10
Jarem Edwards, James S Wilmott, Jason Madore, Tuba Nur Gide, Camelia Quek, Annie Tasker, Angela Ferguson, Jinbiao Chen, Rehana Hewavisenti, Peter Hersey, Thomas Gebhardt, Wolfgang Weninger, Warwick J Britton, Robyn P M Saw, John F Thompson, Alexander M Menzies, Georgina V Long, Richard A Scolyer, Umaimainthan Palendira
Purpose: Therapeutic blockade of immune checkpoints has revolutionized cancer treatment. Durable responses, however, occur in less than half of those treated, and efforts to improve treatment efficacy are confounded by a lack of understanding of the characteristics of the cells that initiate antitumor immune response. Experimental Design: We performed multiparameter flow cytometry and quantitative multiplex immunofluorescence staining on tumor specimens from immunotherapy-naïve melanoma patients and longitudinal biopsy specimen obtained from patients undergoing anti-PD-1 therapy...
March 29, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29580859/stage-iv-melanoma-of-unknown-primary-a-population-based-study-in-the-united-states-from-1973-to-2014
#11
Jeffrey F Scott, Ruzica Z Conic, Cheryl L Thompson, Meg R Gerstenblith, Jeremy S Bordeaux
BACKGROUND: Melanoma of unknown primary (MUP) is incompletely described on a population level. OBJECTIVE: We sought to characterize stage IV MUP in a population-based cancer registry. METHODS: We developed a novel search algorithm to identify cases of stage IV MUP in the Surveillance, Epidemiology, and End Results (SEER)-18 registries from 1973 to 2014. Stage IV melanoma of known primary (MKP) served as a comparison group. Age-standardized incidence rates, demographic characteristics, adjusted disease-specific survival (DSS), and Cox proportional hazard models were calculated for MUP and MKP...
March 23, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29541385/targeting-the-cyclin-dependent-kinase-and-retinoblastoma-axis-overcomes-standard-of-care-resistance-in-braf-v600e-mutant-melanoma
#12
Antoneicka L Harris, Samantha E Lee, Louis K Dawson, Laura A Marlow, Brandy H Edenfield, William F Durham, Thomas J Flotte, Michael Thompson, Daniel L Small, Aidan J Synnott, Svetomir N Markovic, John A Copland
Patient-derived tumor xenograft (PDTX) mouse models were used to discover new therapies for naïve and drug resistant BRAF V600E -mutant melanoma. Tumor histology, oncogenic protein expression, and antitumor activity were comparable between patient and PDTX-matched models thereby validating PDTXs as predictive preclinical models of therapeutic response in patients. PDTX models responsive and non-responsive to BRAF/MEK standard of care (SOC) therapy were used to identify efficacious combination therapies. One such combination includes a CDK4/6 inhibitor that blocks cell cycle progression...
February 16, 2018: Oncotarget
https://www.readbyqxmd.com/read/29538697/risk-stratification-for-melanoma-models-derived-and-validated-in-a-purpose-designed-prospective-cohort
#13
Catherine M Olsen, Nirmala Pandeya, Bridie S Thompson, Jean Claude Dusingize, Penelope M Webb, Adele C Green, Rachel E Neale, David C Whiteman
Background: Risk stratification can improve the efficacy and cost-efficiency of screening programs for early detection of cancer. We sought to derive a risk stratification tool for melanoma that was suitable for the general population using only self-reported information. Methods: We used melanoma risk factor information collected at baseline from QSKIN, a prospective cohort study of Queensland adults age 40 to 69 years at recruitment (n = 41 954). We examined two separate outcomes: 1) invasive melanomas and 2) all melanomas (invasive + in situ) obtained through data linkage to the cancer registry...
March 11, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29473999/melanoma-cases-demonstrate-increased-carrier-frequency-of-phenylketonuria-hyperphenylalanemia-mutations
#14
Joshua Arbesman, Sairekha Ravichandran, Pauline Funchain, Cheryl L Thompson
Identifying novel melanoma genetic risk factors informs screening and prevention efforts. Mutations in the phenylalanine hydroxylase gene (the causative gene in phenylketonuria) lead to reduced pigmentation in untreated phenylketonuria patients, and reduced pigmentation is associated with greater melanoma risk. Therefore, we sought to characterize the relationship between phenylketonuria carrier status and melanoma risk. Using National Newborn Screening Reports, we determined the United States phenylketonuria/hyperphenylalanemia carrier frequency in Caucasians to be 1...
February 23, 2018: Pigment Cell & Melanoma Research
https://www.readbyqxmd.com/read/29438650/updated-evidence-based-clinical-practice-guidelines-for-the-diagnosis-and-management-of-melanoma-definitive-excision-margins-for-primary-cutaneous-melanoma
#15
Michael J Sladden, Omgo E Nieweg, Julie Howle, Brendon J Coventry, John F Thompson
Definitive management of primary cutaneous melanoma consists of surgical excision of the melanoma with the aim of curing the patient. The melanoma is widely excised together with a safety margin of surrounding skin and subcutaneous tissue, after the diagnosis and Breslow thickness have been established by histological assessment of the initial excision biopsy specimen. Sentinel lymph node biopsy should be discussed for melanomas ≥ 1 mm thickness (≥ 0.8 mm if other high risk features) in which case lymphoscintigraphy must be performed before wider excision of the primary melanoma site...
February 19, 2018: Medical Journal of Australia
https://www.readbyqxmd.com/read/29411864/-role-of-sentinel-lymph-node-biopsy-as-a-staging-procedure-in-patients-with-melanoma-a-critical-appraisal-by-omgo-e-nieweg-alan-cooper-and-john-f-thompson
#16
Samuel S Zagarella, Michael J Sladden, Catalin M Popescu, Michael E Bigby
No abstract text is available yet for this article.
February 7, 2018: Australasian Journal of Dermatology
https://www.readbyqxmd.com/read/29360643/tumor-infiltrating-brafv600e-specific-cd4-t-cells-correlated-with-complete-clinical-response-in-melanoma
#17
Joshua R Veatch, Sylvia M Lee, Matthew Fitzgibbon, I-Ting Chow, Brenda Jesernig, Tom Schmitt, Ying Ying Kong, Julia Kargl, A McGarry Houghton, John A Thompson, Martin McIntosh, William W Kwok, Stanley R Riddell
T cells specific for neoantigens encoded by mutated genes in cancers are increasingly recognized as mediators of tumor destruction after immune checkpoint inhibitor therapy or adoptive cell transfer. Unfortunately, most neoantigens result from random mutations and are patient specific, and some cancers contain few mutations to serve as potential antigens. We describe a patient with stage IV acral melanoma who achieved a complete response following adoptive transfer of tumor-infiltrating lymphocytes (TILs). Tumor exome sequencing surprisingly revealed fewer than 30 nonsynonymous somatic mutations, including oncogenic BRAFV600E...
April 2, 2018: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29358500/pembrolizumab-plus-pegylated-interferon-alfa-2b-or-ipilimumab-for-advanced-melanoma-or-renal-cell-carcinoma-dose-finding-results-from-the-phase-ib-keynote-029-study
#18
Michael B Atkins, F Stephen Hodi, John A Thompson, David F McDermott, Wen-Jen Hwu, Donald P Lawrence, Nancy A Dawson, Deborah J Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F Perini, Toni K Choueiri, Antoni Ribas
Purpose: Pembrolizumab monotherapy, ipilimumab monotherapy, and pegylated interferon alfa-2b (PEG-IFN) monotherapy are active against melanoma and renal cell carcinoma (RCC). We explored the safety and preliminary antitumor activity of pembrolizumab combined with either ipilimumab or PEG-IFN in patients with advanced melanoma or RCC. Experimental Design: The phase Ib KEYNOTE-029 study (ClinicalTrials.gov, NCT02089685) included independent pembrolizumab plus reduced-dose ipilimumab and pembrolizumab plus PEG-IFN cohorts...
April 15, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29356588/experiences-of-care-of-adolescents-and-young-adults-with-cancer-in-australia
#19
Victoria White, Gemma Skaczkowski, Kate Thompson, Helen Bibby, Michael Coory, Ross Pinkerton, Wayne Nicholls, Lisa M Orme, Rachel Conyers, Marianne B Phillips, Michael Osborn, Rosemary Harrup, Antoinette Anazodo
PURPOSE: To examine the care experiences of Australian Adolescents and Young Adults (AYAs) with cancer during a period when youth cancer services (YCS) were developing across the country. METHODS: A cross-sectional, self-report survey completed by 207 recently diagnosed AYAs with cancer, recruited from the population-based cancer registries of Australia's two most populous states. AYAs were 15 to 24 years old when diagnosed with any form of cancer (except melanoma <3 mm or stage I/II)...
January 22, 2018: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/29341162/impact-of-genomics-on-the-surgical-management-of-melanoma
#20
REVIEW
P M Ferguson, G V Long, R A Scolyer, J F Thompson
BACKGROUND: Although surgery for early-stage melanoma offers the best chance of cure, recent advances in molecular medicine have revolutionized the management of late-stage melanoma, leading to significant improvements in clinical outcomes. Research into the genomic drivers of disease and cancer immunology has not only ushered in a new era of targeted and immune-based therapies for patients with metastatic melanoma, but has also provided new tools for monitoring disease recurrence and selecting therapeutic strategies...
January 2018: British Journal of Surgery
keyword
keyword
58967
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"